Literature DB >> 1133

Antiarrhythmic, haemodynamic and metabolic effects of 3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride in greyhounds following acute coronary artery ligation.

R J Marshall, J R Parratt.   

Abstract

1 The antiarrhythmic, haemodynamic and metabolic effects of a new amino steroid, ORG6001, have been investigated in experimental acute myocardial infarction in anaesthetized greyhounds. 2 ORG6001 administered either intravenously (2-10 mg/kg) or orally (50 mg/kg) significantly reduced the incidence of ventricular ectopic beats in the first 30 min after ligation of the left anterior descending coronary artery. 3 In dogs pretreated with ORG6001, metabolic changes indicative of myocardial ischaemia (lactate production and potassium efflux) were less marked than those occurring in control animals. 4 Antiarrhythmic doses of ORG6001 caused only minimal transient haemodynamic effects. 5 These results suggest that ORG6001 may possess distinct advantages over presently-used antiarrhythmic drugs in the prevention and treatment of the early arrhythmias which occur after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133      PMCID: PMC1666686          DOI: 10.1111/j.1476-5381.1975.tb06939.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Evidence that serum potassium is not the etiological agent in ventricular fibrillation following coronary artery occlusion.

Authors:  J WEXLER; H H PATT
Journal:  Am Heart J       Date:  1960-10       Impact factor: 4.749

2.  Excitatory factors in ventricular tachycardia resulting from myocardial ischemia; potassium a major excitant.

Authors:  A S HARRIS; A BISTENI; R A RUSSELL; J C BRIGHAM; J E FIRESTONE
Journal:  Science       Date:  1954-02-12       Impact factor: 47.728

3.  Acute phase of myocardial infarction.

Authors:  A A Adgey; J D Allen; J S Geddes; R G James; S W Webb; S A Zaidi; J F Pantridge
Journal:  Lancet       Date:  1971-09-04       Impact factor: 79.321

4.  Coronary sinus lactate measurements in assessment of myocardial ischemia. Comparison with changes in lactate-pyruvate and beta-hydroxybutyrate-acetoacetate ratios and with release of hydrogen, phosphate and potassium ions from the heart.

Authors:  L H Opie; P Owen; M Thomas; R Samson
Journal:  Am J Cardiol       Date:  1973-09-07       Impact factor: 2.778

5.  Changes in blood flow and oxygen consumption in normal and ischaemic regions of the myocardium following acute coronary artery ligation.

Authors:  R J Marshall; J R Parratt; I M Ledingham
Journal:  Cardiovasc Res       Date:  1974-03       Impact factor: 10.787

6.  The effect of noradrenaline on blood flow and oxygen consumption in normal and ischemic areas of myocardium.

Authors:  R J Marhsall; J R Parratt
Journal:  Am Heart J       Date:  1973-11       Impact factor: 4.749

7.  Assessment of hypoxia in the human heart.

Authors:  R Gorlin
Journal:  Cardiology       Date:  1972       Impact factor: 1.869

8.  Premature mortality from coronary heart disease. The Framingham study.

Authors:  T Gordon; W B Kannel
Journal:  JAMA       Date:  1971-03-08       Impact factor: 56.272

Review 9.  Antiarrhythmic agents. I. Mechanisms of action and clinical pharmacology.

Authors:  D T Mason; A N DeMaria; E A Amsterdam; R Zelis; R A Massumi
Journal:  Drugs       Date:  1973       Impact factor: 9.546

10.  Ventricular arrhythmias and K+ transfer during myocardial ischemia and intervention with procaine amide, insulin, or glucose solution.

Authors:  T J Regan; M A Harman; P H Lehan; W M Burke; H A Oldewurtel
Journal:  J Clin Invest       Date:  1967-10       Impact factor: 14.808

View more
  17 in total

1.  Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism.

Authors:  L A Salako; V Williams; J H Wittig
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

2.  Decisions, directions, defects and fellow disciples (A rückblick of 50 years of basic medical research).

Authors:  James Roy Parratt
Journal:  Exp Clin Cardiol       Date:  2010

3.  Comparative effects of a new orally active antidysrhythmic agent, Organon 6001, on the cardiac action potential of human ventricular muscle and sheep Purkinje fibres [proceedings].

Authors:  K A Kane
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

4.  Coronary artery ligation in anaesthetized rats as a model for the assessment of antidysrhythmic activity; the effects of lignocaine, propranolol and ORG 6001 [proceedings].

Authors:  K Kane; F McDonald; J R Parratt
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

5.  The haemodynamic and metabolic effects of MG 8926, a prospective antidysrhythmic and antianginal agent.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1977-02       Impact factor: 8.739

6.  The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs.

Authors:  R J Marshall; A W Muir
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

7.  Proceedings of the British Pharmacological Society. 16--18th December, 1980.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-05       Impact factor: 8.739

8.  The antidysrhythmic aminosteroid, ORG 6001, reduces the ST-segment elevation produced by coronary occlusion in the dog.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1977-10       Impact factor: 8.739

9.  Prophylactic lignocaine and early post-coronary artery occlusion dysrhythmias in anaesthetized greyhounds.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  Electrophysiological and other effects on rabbit hearts of CCI22277, a new steroidal antiarrhythmic drug.

Authors:  T J Campbell; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.